<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Advicenne Sa — News on 6ix</title>
    <link>https://6ix.com/company/advicenne-sa</link>
    <description>Latest news and press releases for Advicenne Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 24 Apr 2026 16:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/advicenne-sa" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d52976beedb30cb6f6a824.webp</url>
      <title>Advicenne Sa</title>
      <link>https://6ix.com/company/advicenne-sa</link>
    </image>
    <item>
      <title>Advicenne 2025 Universal Registration Document Made Available</title>
      <link>https://6ix.com/company/advicenne-sa/news/advicenne-2025-universal-registration-document-made-available-1</link>
      <guid isPermaLink="true">https://6ix.com/company/advicenne-sa/news/advicenne-2025-universal-registration-document-made-available-1</guid>
      <pubDate>Fri, 24 Apr 2026 16:00:00 GMT</pubDate>
      <description>PARIS, April 24, 2026--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today that its 2025 Universal Registration Document has been filed with the French Autorité des Marchés Financiers (AMF).</description>
    </item>
    <item>
      <title>Advicenne Reports Its 2025 Annual Financial Results</title>
      <link>https://6ix.com/company/advicenne-sa/news/advicenne-reports-its-2025-annual-financial-results-1</link>
      <guid isPermaLink="true">https://6ix.com/company/advicenne-sa/news/advicenne-reports-its-2025-annual-financial-results-1</guid>
      <pubDate>Thu, 26 Mar 2026 19:09:00 GMT</pubDate>
      <description>PARIS, March 26, 2026--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today its 2025 financial results, and provides an update on its activities.</description>
    </item>
    <item>
      <title>Advicenne: Official Reimbursement of Sibnayal® for the Treatment of dRTA in France</title>
      <link>https://6ix.com/company/advicenne-sa/news/advicenne-official-reimbursement-of-sibnayalr-for-the-treatment-of-drta-in-france-1</link>
      <guid isPermaLink="true">https://6ix.com/company/advicenne-sa/news/advicenne-official-reimbursement-of-sibnayalr-for-the-treatment-of-drta-in-france-1</guid>
      <pubDate>Mon, 02 Feb 2026 06:00:00 GMT</pubDate>
      <description>PARIS, February 02, 2026--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today that Sibnayal® (a fixed combination of potassium citrate and potassium bicarbonate) is now reimbursed by the French social security system for the treatment of distal Renal Tubular Acidosis (dRTA).</description>
    </item>
    <item>
      <title>Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in UAE</title>
      <link>https://6ix.com/company/advicenne-sa/news/advicenne-receives-marketing-authorization-and-reimbursement-for-sibnayalr-in-uae-1</link>
      <guid isPermaLink="true">https://6ix.com/company/advicenne-sa/news/advicenne-receives-marketing-authorization-and-reimbursement-for-sibnayalr-in-uae-1</guid>
      <pubDate>Tue, 27 Jan 2026 06:00:00 GMT</pubDate>
      <description>PARIS, January 27, 2026--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, obtains both marketing authorization (MA) and reimbursement status for its drug Sibnayal® (fixed combination of potassium citrate and potassium bicarbonate) in the United Arab Emirates (UAE) for the treatment of distal Renal Tubular Acidosis (dRTA).</description>
    </item>
    <item>
      <title>Advicenne: 2025 Full Year Sales</title>
      <link>https://6ix.com/company/advicenne-sa/news/advicenne-2025-full-year-sales-1</link>
      <guid isPermaLink="true">https://6ix.com/company/advicenne-sa/news/advicenne-2025-full-year-sales-1</guid>
      <pubDate>Thu, 22 Jan 2026 17:00:00 GMT</pubDate>
      <description>PARIS, January 22, 2026--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announced today that its 2025 sales amounted to €5.73 million, up 18.4% compared to the previous financial year. Revenue does not include royalties from partners on sales made in their respective territories, estimated at €1.0 million for 2025 and double t</description>
    </item>
    <item>
      <title>Advicenne: 2026 Financial Calendar</title>
      <link>https://6ix.com/company/advicenne-sa/news/advicenne-2026-financial-calendar-1</link>
      <guid isPermaLink="true">https://6ix.com/company/advicenne-sa/news/advicenne-2026-financial-calendar-1</guid>
      <pubDate>Tue, 20 Jan 2026 17:00:00 GMT</pubDate>
      <description>PARIS, January 20, 2026--Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces its 2026 financial communication calendar.</description>
    </item>
    <item>
      <title>Advicenne: FDA Has Accepted for Review the Marketing Authorization Application for Sibnayal® in the United States for the Treatment of dRTA</title>
      <link>https://6ix.com/company/advicenne-sa/news/advicenne-fda-has-accepted-for-review-the-marketing-authorization-application-for-sibnayalr-in-the-united-states-for-the-treatment-of-drta-1</link>
      <guid isPermaLink="true">https://6ix.com/company/advicenne-sa/news/advicenne-fda-has-accepted-for-review-the-marketing-authorization-application-for-sibnayalr-in-the-united-states-for-the-treatment-of-drta-1</guid>
      <pubDate>Mon, 19 Jan 2026 06:30:00 GMT</pubDate>
      <description>PARIS, January 19, 2026--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces that the FDA (Food and Drug Administration) has accepted for review the New Drug Application (NDA) for Sibnayal® (ADV7103), a fixed combination of potassium citrate and potassium bicarbonate for the treatment of distal Renal Tubular Acidosis (dRT</description>
    </item>
    <item>
      <title>Advicenne Has Successfully Renewed the Marketing Authorization of Sibnayal® in European Union</title>
      <link>https://6ix.com/company/advicenne-sa/news/advicenne-has-successfully-renewed-the-marketing-authorization-of-sibnayalr-in-european-union-1</link>
      <guid isPermaLink="true">https://6ix.com/company/advicenne-sa/news/advicenne-has-successfully-renewed-the-marketing-authorization-of-sibnayalr-in-european-union-1</guid>
      <pubDate>Mon, 12 Jan 2026 06:30:00 GMT</pubDate>
      <description>PARIS, January 12, 2026--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, obtains the renewal of its Marketing Authorization (MA) for Sibnayal® (fixed combination of potassium citrate and potassium bicarbonate) for the treatment of distal Renal Tubular Acidosis (dRTA) in the European Union.</description>
    </item>
    <item>
      <title>Advicenne Has Submitted to US FDA the Registration Application for Sibnayal® in dRTA Treatment</title>
      <link>https://6ix.com/company/advicenne-sa/news/advicenne-has-submitted-to-us-fda-the-registration-application-for-sibnayalr-in-drta-treatment-1</link>
      <guid isPermaLink="true">https://6ix.com/company/advicenne-sa/news/advicenne-has-submitted-to-us-fda-the-registration-application-for-sibnayalr-in-drta-treatment-1</guid>
      <pubDate>Tue, 04 Nov 2025 10:29:00 GMT</pubDate>
      <description>PARIS, November 04, 2025--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces the submission of the registration application for Sibnayal® (fixed-dose combination of potassium citrate and potassium bicarbonate) for the treatment of distal Renal Tubular Acidosis (dRTA) to the US Food and Drug Administration (US FDA). Sibna</description>
    </item>
    <item>
      <title>Advicenne Reports First Half Financial Results as of June 30, 2025, and Updates on Its Activities</title>
      <link>https://6ix.com/company/advicenne-sa/news/advicenne-reports-first-half-financial-results-as-of-june-30-2025-and-updates-on-its-activities-1</link>
      <guid isPermaLink="true">https://6ix.com/company/advicenne-sa/news/advicenne-reports-first-half-financial-results-as-of-june-30-2025-and-updates-on-its-activities-1</guid>
      <pubDate>Fri, 19 Sep 2025 16:00:00 GMT</pubDate>
      <description>PARIS, September 19, 2025--Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, today reports its 2025 first half financial results, as approved on September 19, 2025 by the Board of Directors. The first half financial report is available on the Company’s website: www.advicenne.com.</description>
    </item>
    <item>
      <title>Advicenne Announces the Publication in Orphanet Journal of Rare Diseases of the Long-term European Study Results of dRTA Treatment Using ADV7103</title>
      <link>https://6ix.com/company/advicenne-sa/news/advicenne-announces-the-publication-in-orphanet-journal-of-rare-diseases-of-the-long-term-european-study-results-of-drta-treatment-using-adv7103-1</link>
      <guid isPermaLink="true">https://6ix.com/company/advicenne-sa/news/advicenne-announces-the-publication-in-orphanet-journal-of-rare-diseases-of-the-long-term-european-study-results-of-drta-treatment-using-adv7103-1</guid>
      <pubDate>Tue, 26 Aug 2025 16:00:00 GMT</pubDate>
      <description>PARIS, August 26, 2025--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces the publication in Orphanet Journal of Rare Disease (OJRD) of the long-term results of the pivotal study of ADV7103 in the treatment of distal renal tubular acidosis (dRTA).</description>
    </item>
    <item>
      <title>Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in Saudi Arabia</title>
      <link>https://6ix.com/company/advicenne-sa/news/advicenne-receives-marketing-authorization-and-reimbursement-for-sibnayalr-in-saudi-arabia-1</link>
      <guid isPermaLink="true">https://6ix.com/company/advicenne-sa/news/advicenne-receives-marketing-authorization-and-reimbursement-for-sibnayalr-in-saudi-arabia-1</guid>
      <pubDate>Mon, 28 Jul 2025 05:30:00 GMT</pubDate>
      <description>PARIS, July 28, 2025--Regulatory News: Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, obtains marketing authorization (MA) and reimbursement status for Sibnayal® (a fixed combination of potassium citrate and potassium bicarbonate) in the Kingdom of Saudi Arabia (KSA).</description>
    </item>
    <item>
      <title>Advicenne Reports its H1 2025 Sales</title>
      <link>https://6ix.com/company/advicenne-sa/news/advicenne-reports-its-h1-2025-sales-1</link>
      <guid isPermaLink="true">https://6ix.com/company/advicenne-sa/news/advicenne-reports-its-h1-2025-sales-1</guid>
      <pubDate>Fri, 25 Jul 2025 05:30:00 GMT</pubDate>
      <description>PARIS, July 25, 2025--Regulatory News: Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, reports first half of 2025 sales of €2.6 million, up 9% compared to the first half of 2024. The reported turnover does not include royalties to be received from partners during this period.</description>
    </item>
    <item>
      <title>Advicenne Raises 2.6 Million Euros in Its Capital Increase and Extends Its Financial Visibility</title>
      <link>https://6ix.com/company/advicenne-sa/news/advicenne-raises-26-million-euros-in-its-capital-increase-and-extends-its-financial-visibility-1</link>
      <guid isPermaLink="true">https://6ix.com/company/advicenne-sa/news/advicenne-raises-26-million-euros-in-its-capital-increase-and-extends-its-financial-visibility-1</guid>
      <pubDate>Mon, 21 Jul 2025 18:52:00 GMT</pubDate>
      <description>PARIS, July 21, 2025--Regulatory News: Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases (the &quot;Company&quot;), raised a total of nearly €2.6 million through the issue of 1,895,948 New Shares at a unit price of €1.35 as part of the capital increase through the issue of new ordinary shares (the &quot;New Shares&quot;) with shareholders&apos; pre-emptive subscription rights</description>
    </item>
    <item>
      <title>Advicenne 2024 Universal Registration Document Made Available</title>
      <link>https://6ix.com/company/advicenne-sa/news/advicenne-2024-universal-registration-document-made-available-1</link>
      <guid isPermaLink="true">https://6ix.com/company/advicenne-sa/news/advicenne-2024-universal-registration-document-made-available-1</guid>
      <pubDate>Tue, 29 Apr 2025 16:00:00 GMT</pubDate>
      <description>PARIS, April 29, 2025--Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces today that its 2024 Universal Registration Document has been filed with the French Autorité des Marchés Financiers (AMF).</description>
    </item>
  </channel>
</rss>